Roche buys cancer drugmaker Ignyta | January 1, 2018 Issue - Vol. 96 Issue 1 | Chemical & Engineering News
Volume 96 Issue 1 | p. 13 | Concentrates
Issue Date: January 1, 2018

Roche buys cancer drugmaker Ignyta

By Ryan Cross
Department: Business
Keywords: Oncology, Ignyta, Roche, cancer, tyrosine kinase, entrectinib

Swiss drug giant Roche will expand its oncology pipeline with a $1.7 billion purchase of the San Diego-based drugmaker Ignyta. The deal is part of a growing trend to design cancer drugs that target tumors with particular genetic mutations, as opposed to a particular tissue. Ignyta’s lead cancer compound, entrectinib, is a small-molecule tyrosine kinase inhibitor. The firm has three other small-molecule programs for cancer, including one compound the company says could boost the innate immune response to tumors.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment